{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T05:35:53Z","timestamp":1788068153973,"version":"build-2784847793"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Rheumatol"],"DOI":"10.1186\/s41927-025-00559-y","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:27:19Z","timestamp":1761121639000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacological management of spondyloarthritis associated with inflammatory bowel disease: a systematic review of efficacy, safety, and emerging therapies"],"prefix":"10.1186","volume":"9","author":[{"given":"Mohammed","family":"Khalil Jnyah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imane El","family":"Mezouar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nessrine","family":"Akasbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taoufik","family":"Harzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"issue":"1","key":"559_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","volume":"142","author":"NA Molodecky","year":"2012","unstructured":"Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46\u2013e5442.","journal-title":"Gastroenterology"},{"issue":"8","key":"559_CR2","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1097\/MIB.0000000000000392","volume":"21","author":"SR Vavricka","year":"2015","unstructured":"Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2015;21(8):1982\u201392.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"559_CR3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1136\/gut.42.3.387","volume":"42","author":"TR Orchard","year":"1998","unstructured":"Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998;42(3):387\u201391.","journal-title":"Gut"},{"issue":"1","key":"559_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/ajg.2010.343","volume":"106","author":"SR Vavricka","year":"2011","unstructured":"Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106(1):110\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"26","key":"559_CR5","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1056\/NEJMra1406182","volume":"374","author":"JD Taurog","year":"2016","unstructured":"Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;374(26):2563\u201374.","journal-title":"N Engl J Med"},{"issue":"12","key":"559_CR6","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/s41584-018-0097-2","volume":"14","author":"JT Rosenbaum","year":"2018","unstructured":"Rosenbaum JT, Asquith M. The Microbiome and HLA-B27\u2013associated acute anterior uveitis. Nat Rev Rheumatol. 2018;14(12):705\u201314.","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"559_CR7","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41584-020-0454-9","volume":"16","author":"E Gracey","year":"2020","unstructured":"Gracey E, Verheul MK, Budde E, et al. The Immunopathogenesis of spondyloarthritis: insights from animal models and human studies. Nat Rev Rheumatol. 2020;16(8):434\u201347.","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"559_CR8","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"W Hueber","year":"2012","unstructured":"Hueber W, Sands BE, Lewitzky S, Vandermeulebroecke M, Reinisch W, Higgins PD, et al. Secukinumab, a human anti\u2013IL-17A monoclonal antibody, for moderate to severe crohn\u2019s disease: unexpected results of a randomised controlled trial. Gut. 2012;61(12):1693\u2013700.","journal-title":"Gut"},{"issue":"5","key":"559_CR9","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","volume":"66","author":"JF Colombel","year":"2017","unstructured":"Colombel JF, Sands BE, Rutgeerts P, Sandborn WJ, Danese S, D\u2019Haens G, et al. The safety of Vedolizumab for ulcerative colitis and crohn\u2019s disease. Gut. 2017;66(5):839\u201351.","journal-title":"Gut"},{"issue":"1","key":"559_CR10","doi-asserted-by":"crossref","first-page":"e001512","DOI":"10.1136\/rmdopen-2021-001594","volume":"7","author":"V Furer","year":"2021","unstructured":"Furer V, Kishimoto M, Pereira RM, Haliloglu S, Kaeley GS, Baraliakos X, et al. Efficacy and safety of systemic glucocorticoids in axial spondyloarthritis: a systematic review and meta-analysis. RMD Open. 2021;7(1):e001512.","journal-title":"RMD Open"},{"issue":"1","key":"559_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","volume":"11","author":"F Gomoll\u00f3n","year":"2017","unstructured":"Gomoll\u00f3n F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. 3rd European Evidence-based consensus on the diagnosis and management of crohn\u2019s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11(1):3\u201325.","journal-title":"J Crohns Colitis"},{"issue":"6","key":"559_CR12","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landew\u00e9 R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS\u2013EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978\u201391.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"559_CR13","first-page":"2116","volume":"74","author":"J Sieper","year":"2015","unstructured":"Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, et al. Intra-articular and periarticular glucocorticoid injections for peripheral arthritis and enthesitis in spondyloarthritis: evidence-based guidance. Ann Rheum Dis. 2015;74(12):2116\u201323.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"559_CR14","first-page":"1037","volume":"14","author":"ECCO Guidelines","year":"2020","unstructured":"ECCO Guidelines. Extraintestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2020;14(10):1037\u201343.","journal-title":"J Crohns Colitis"},{"issue":"6","key":"559_CR15","first-page":"806","volume":"80","author":"EULAR Recommendations","year":"2021","unstructured":"EULAR Recommendations. Management of spondyloarthritis. Ann Rheum Dis. 2021;80(6):806\u201323.","journal-title":"Ann Rheum Dis"},{"key":"559_CR16","first-page":"175628482311521","volume":"16","author":"C Herrera-deGuise","year":"2023","unstructured":"Herrera-deGuise C, et al. Janus kinase inhibitors in inflammatory bowel disease: a systematic review. Ther Adv Gastroenterol. 2023;16:17562848231152191.","journal-title":"Ther Adv Gastroenterol"},{"key":"559_CR17","first-page":"29","volume":"98","author":"S Li","year":"2022","unstructured":"Li S, et al. Efficacy and safety of Janus kinase inhibitors for active ankylosing spondylitis: a systematic review and meta-analysis. Eur J Intern Med. 2022;98:29\u201337.","journal-title":"Eur J Intern Med"},{"issue":"2","key":"559_CR18","first-page":"e14688","volume":"27","author":"K Ono","year":"2024","unstructured":"Ono K, et al. Janus kinase inhibitors in spondyloarthritis and inflammatory bowel disease. Int J Rheum Dis. 2024;27(2):e14688.","journal-title":"Int J Rheum Dis"},{"issue":"7","key":"559_CR19","first-page":"1761","volume":"69","author":"K Fansiwala","year":"2024","unstructured":"Fansiwala K, et al. Janus kinase inhibitors for ulcerative colitis: current status and future prospects. Dig Dis Sci. 2024;69(7):1761\u201373.","journal-title":"Dig Dis Sci"},{"issue":"1","key":"559_CR20","first-page":"15","volume":"80","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, et al. JAK inhibitors: safety considerations. Ann Rheum Dis. 2021;80(1):15\u201324.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"559_CR21","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","volume":"18","author":"KL Winthrop","year":"2022","unstructured":"Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2022;18(4):234\u201345.","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl 1","key":"559_CR22","doi-asserted-by":"publisher","first-page":"i17","DOI":"10.1093\/rheumatology\/key225","volume":"58","author":"PC Taylor","year":"2019","unstructured":"Taylor PC. Clinical safety of Janus kinase inhibitors in rheumatoid arthritis. Rheumatology. 2019;58(Suppl 1):i17\u201326.","journal-title":"Rheumatology"},{"issue":"3","key":"559_CR23","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s40744-024-00671-4","volume":"11","author":"GR Burmester","year":"2024","unstructured":"Burmester GR, Stigler J, Rubbert-Roth A, Tanaka Y, Azevedo VF, Coombs D, Lagunes I, Lippe R, Wung P, Gensler LS. Rheumatol Ther. 2024;11(3):737\u201353.","journal-title":"Rheumatol Ther"},{"issue":"3","key":"559_CR24","first-page":"245","volume":"17","author":"C Felice","year":"2023","unstructured":"Felice C, et al. Choosing the most appropriate biologic therapy for crohn\u2019s disease according to extra-intestinal manifestations. Expert Rev Gastroenterol Hepatol. 2023;17(3):245\u201359.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"4","key":"559_CR25","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.3390\/ijms23042149","volume":"23","author":"TL Parigi","year":"2022","unstructured":"Parigi TL, et al. IL-23 p19 inhibitors for inflammatory bowel diseases: state of the Art. Int J Mol Sci. 2022;23(4):2149.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"559_CR26","first-page":"222","volume":"80","author":"D McGonagle","year":"2021","unstructured":"McGonagle D, et al. Why Inhibition of IL-23 had failed to impact axial spondyloarthritis: a mechanistic analysis. Ann Rheum Dis. 2021;80(2):222\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"10395","key":"559_CR27","first-page":"1847","volume":"403","author":"V Jairath","year":"2024","unstructured":"Jairath V, et al. TYK2 Inhibition in immune-mediated diseases: the emerging evidence. Lancet. 2024;403(10395):1847\u201359.","journal-title":"Lancet"},{"issue":"8","key":"559_CR28","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1080\/17474124.2019.1644167","volume":"13","author":"C Romano","year":"2019","unstructured":"Romano C, et al. Choosing the most appropriate biologic therapy for crohn\u2019s disease with EIMs. Expert Rev Gastroenterol Hepatol. 2019;13(8):751\u201364.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"559_CR29","first-page":"11","volume":"17","author":"IG-IBD\/SIR Recommendations","year":"2023","unstructured":"IG-IBD\/SIR Recommendations. Management of patients with IBD-associated spondyloarthritis. J Crohns Colitis. 2023;17(1):11\u201325.","journal-title":"J Crohns Colitis"},{"issue":"6","key":"559_CR30","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.3390\/jcm12062210","volume":"12","author":"D Ben Nessib","year":"2023","unstructured":"Ben Nessib D, Boussetta N, Fourati S, Ya\u00efch S, Mkaouar F, Boughattas NA. Prevalence of self-reported spondyloarthritis features in patients with inflammatory bowel disease: an observational study. J Clin Med. 2023;12(6):2210.","journal-title":"J Clin Med"},{"issue":"8","key":"559_CR31","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s10067-013-2259-6","volume":"32","author":"R Peluso","year":"2013","unstructured":"Peluso R, et al. Enteropathic spondyloarthritis: from diagnosis to treatment. Clin Rheumatol. 2013;32(8):1199\u2013210.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"559_CR32","first-page":"615","volume":"35","author":"MM Luchetti","year":"2017","unstructured":"Luchetti MM, et al. Adalimumab efficacy in enteropathic spondyloarthritis. Clin Exp Rheumatol. 2017;35(4):615\u201322.","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"559_CR33","first-page":"873","volume":"17","author":"P Michetti","year":"2023","unstructured":"Michetti P, et al. Enteropathic spondyloarthritis: Real-world data. J Crohns Colitis. 2023;17(6):873\u201381.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"559_CR34","first-page":"332","volume":"72","author":"C Stolwijk","year":"2013","unstructured":"Stolwijk C, van Tubergen A, Ramiro S, van der Heijde D, Dougados M, van der Linden S. Spondyloarthritis in inflammatory bowel disease cohorts: a population-based study of prevalence and clinical characteristics. Ann Rheum Dis. 2013;72(3):332\u20136.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"559_CR35","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.3390\/ijms24021529","volume":"24","author":"D Cozzi","year":"2023","unstructured":"Cozzi D, et al. Axial spondyloarthritis and inflammatory bowel disease: therapeutic application of emerging biologics. Int J Mol Sci. 2023;24(2):1529.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"559_CR36","doi-asserted-by":"crossref","first-page":"105498","DOI":"10.1016\/j.jbspin.2022.105498","volume":"90","author":"P Goupille","year":"2023","unstructured":"Goupille P, Dougados M, Combe B. Update on therapeutic management of spondyloarthritis associated with inflammatory bowel disease. Joint Bone Spine. 2023;90(2):105498.","journal-title":"Joint Bone Spine"},{"issue":"9","key":"559_CR37","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/17474124.2018.1503947","volume":"12","author":"C Felice","year":"2018","unstructured":"Felice C, et al. Choosing the most appropriate biologic therapy for crohn\u2019s disease according to extra-intestinal manifestations. Expert Rev Gastroenterol Hepatol. 2018;12(9):873\u201385.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"5","key":"559_CR38","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.cgh.2019.08.043","volume":"18","author":"G De Marco","year":"2020","unstructured":"De Marco G, et al. Anti-TNF therapy in extraintestinal manifestations of IBD: A meta-analysis. Clin Gastroenterol Hepatol. 2020;18(5):1112\u2013e233.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"559_CR39","doi-asserted-by":"crossref","unstructured":"McCormack MD, et al. Emerging role of dual biologic therapy for the treatment of refractory IBD: a case series review. Front Immunol. 2023;11(12):2621\u201330.","DOI":"10.12998\/wjcc.v11.i12.2621"},{"key":"559_CR40","unstructured":"Lignou AZ, et al. Combination targeted therapy in inflammatory bowel disease: a retrospective cohort assessment. Dig Liver Dis. 2025;57(5): 653\u201362."},{"key":"559_CR41","doi-asserted-by":"crossref","unstructured":"Savin E, et al. Biologic treatment modification efficacy in concurrent IBD and ankylosing spondylitis: a retrospective cohort study. J Clin Med. 2023;12(22):7151.","DOI":"10.3390\/jcm12227151"},{"key":"559_CR42","doi-asserted-by":"crossref","unstructured":"Hirten RP, et al. Vedolizumab combined with Tofacitinib or anti-TNF therapy in refractory IBD with spa: case series. Clin Gastroenterol Hepatol. 2018;16(9): 1374\u20136.","DOI":"10.1016\/j.cgh.2018.02.024"},{"key":"559_CR43","doi-asserted-by":"crossref","unstructured":"Valero-Mart\u00ednez C, et al. Dual targeted therapy in refractory spondyloarthritis and psoriatic arthritis with concomitant IBD: a multicenter real-world cohort. Front Immunol. 2023;14:1283251.","DOI":"10.3389\/fimmu.2023.1283251"},{"issue":"2","key":"559_CR44","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3390\/biom15020222","volume":"15","author":"G Altieri","year":"2025","unstructured":"Altieri G, et al. Dual-targeted therapy in IBD: efficacy and safety overview. Biomolecules. 2025;15(2):222.","journal-title":"Biomolecules"},{"key":"559_CR45","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.ejim.2019.04.015","volume":"64","author":"MM Luchetti","year":"2019","unstructured":"Luchetti MM, Benfaremo D, Bendia E, Bolognini L, Fava G, Marini F, Di Sario A, Ciferri M, Di Nicola F, Marconi V, Perini L, Manfredi L, Pomponio G, Mosca P, Benedetti A, Gabrielli A. Eur J Intern Med. 2019;64:76\u201384.","journal-title":"Eur J Intern Med"}],"container-title":["BMC Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00559-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41927-025-00559-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41927-025-00559-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:27:25Z","timestamp":1761121645000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcrheumatol.biomedcentral.com\/articles\/10.1186\/s41927-025-00559-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["559"],"URL":"https:\/\/doi.org\/10.1186\/s41927-025-00559-y","relation":{},"ISSN":["2520-1026"],"issn-type":[{"value":"2520-1026","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this study is a systematic review of published literature, ethics approval and patient consent were not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable, as no individual patient data are included in this systematic review.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"125"}}